More than half of patients receiving systemic therapies for the treatment of advanced epithelioid sarcoma (ES) experience adverse events, according to a study.
In this retrospective study, the medical records of 74 patients with advanced ES who were starting first-line or ≥2 lines of systemic therapy, were reviewed. In total, 85% had metastatic disease. The most common first-line regimens were anthracycline-based (54%) or gemcitabine-based (24%).
The real-world overall response rate and real-world duration of response for patients on first-line systemic therapy was 15% and 20%. The median real-world duration of response, median real-world progression-free survival, the median overall survival was 3.3 months, 2.5 months, and 15.2 months for these patients.
The real-world overall response rate and real-world disease control rate (defined as stable disease for ≥32 weeks or any duration of response) for patients on ≥2 lines of systemic therapy were 9% and 20%. The median real-world duration of response and median real-world progression-free survival was 4.5 months, 6.0 months for these patients.
Adverse events were reported in 51.4% of patients, with febrile neutropenia (14%), pain (10%), anemia, dyspnea, fever, thrombocytopenia, or transaminitis (5% each), the most reported.
Gounder MM, Merriam P, Ratan R, et al. Real-world outcomes of patients with locally advanced or metastatic epithelioid sarcoma. Cancer. 2020;DOI: 10.1002/cncr.33365. Epub ahead of print. PMID: 33296083.